| |
Tuesday, August 27, 2024 | 12pm ET / 9am PT Join us for a one-hour, comprehensive discussion on the importance of leveraging federated AI for innovative data collection in real-world research. Register now.
|
|
Today’s Big NewsAug 16, 2024 |
| By Angus Liu Genentech will close its cancer immunology department to form a single oncology research organization. Unit head and renowned cell biologist Ira Mellman, who has been with the company for 17 years, will depart in the coming months. |
|
|
|
By Darren Incorvaia Lykos Therapeutics is capping off an awful week with a massive reorganization, laying off about 75% of staff in the aftermath of an FDA rejection and the retraction of three research papers on the biotech’s MDMA treatment due to protocol violations at a clinical trial site. |
By James Waldron Pfizer and BioNTech may have a strong pedigree in the mRNA vaccine game, but, when it comes to flu, they’ve run up against the same problem as their peers—neutralizing influenza strain B. |
By Angus Liu To Juergen Eckhardt, M.D., who leads both the investment arm Leaps by Bayer and the pharma business development team, the ongoing overhaul won’t disrupt the German company’s dealmaking appetite. |
By Darren Incorvaia Céline Dion stands alone as a singer, a chart-topping ballad-belter who recorded some of the most iconic songs of all time, including “My Heart Will Go On” from the "Titanic" soundtrack. But, in 2022, Dion made headlines not for her one-in-a-million voice, but for a one-in-a-million diagnosis: a rare neurological disease called stiff-person syndrome. |
By Darren Incorvaia,Zoey Becker,Gabrielle Masson Tina Albertson, M.D., Ph.D., is taking over the top doctor spot at CRISPR-focused Caribou Biosciences. |
By Conor Hale The Edison system uses vibrations from sound waves to create bubbles of gas within a tumor, with enough energy to destroy the targeted tissue. |
By Heather Landi The Chicago-based healthcare advisory firm announced Wednesday that it had entered into a definitive agreement to receive a majority investment from funds managed by Blackstone. |
By Angus Liu Merck licensed a bispecific from a Chinese biotech with plans to target oncology and autoimmune diseases. Legend Biotech is taking a close at its business as M&A has emerged as an option. A large number of missing adverse events in South Korea triggered a full-scale check-up during the FDA's review of Amgen's Imdelltra. And more. |
Fierce podcastsDon’t miss an episode |
| | In this week’s episode of “The Top Line,” Fierce executive editor Eric Sagonowsky chats with Angus Liu about his feature story on the three TROP2 front-runners. |
|
|---|
|
|
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
